MarketInOut Stock Screener Log In | Sign Up
 

AC Immune S.A.

NASDAQ • Healthcare • Biotechnology • Quote as of 09/18/2026
AC Immune S.A. stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization266.46 mln
Float46.46 mln
Earnings Date11/10/2026

Piotroski F-Score

1 / 9
Very weak

Beneish M-Score

5.26
Highly suspicious

1-Year Forecast

8.42
Transformational upside

Relative Strength

13 / 100
Significantly lagging

Debt / Equity

0.12
Very low leverage

Pre-Tax Margin

-248%
Severely loss-making

Business Description

AC Immune SA is a Switzerland-based clinical-stage company focused on fighting neurodegenerative diseases by targeting the misfolded proteins that drive conditions such as Alzheimer's and Parkinson's. Its two core platforms produce both biological therapies and small-molecule drugs designed to seek out and act on these harmful proteins, supporting a broad pipeline of treatments and diagnostic tools. The company works alongside major partners including Genentech, Eli Lilly, and Janssen Pharmaceuticals to advance its programs through development.

Key Fundamentals

EPS-0.52
ROE-87.55
RPS0.22
ROIC-30.62
ROA-27.05
Interest Cover-263
EBITDA, mln-52.55
EV / EBITDA-3.36
EV / EBIT-3.26
Revenue, mln21.93
EV / Revenue8.04

Quote Details

Last 2.63
Change -0.05 (-1.87%)
Open 2.69
Volume 68,459
Turnover 180,047
Average Volume 173,528

Financial Ratios

Pre-Tax Profit Margin-248
Leverage Ratio4.28
Current Ratio0.93
Price / Book6.02
Debt / Equity0.12
Price / Sales12.69

Financial Strength

Altman Z-Score-3.98
Piotroski F-Score 1 / 9
Beneish M-Score5.26
1-Year Target Price8.42
Short Ratio14.26
Short % of Float7.09

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.71% 15 / 100   
1 Month 1.94% 81 / 100   
2 Months 16.37% 87 / 100   
6 Months -10.85% 24 / 100   
1 Year 6.91% 56 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us